Immatics Biotechnologies Gmbh

Michael Roemer

Jens Fritsche

Oliver Schoor

Daniel Johannes Kowalewski

Heiko Schuster

Toni Weinschenk

Harpreet Singh

Gisela Schimmack

Jens Hukelmann

Chih-Chiang Tsou

Ricarda Hannen

Florian Koehler

Annika Sonntag

Christoph Schraeder

Lena Wullkopf

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Peptides displayed by HLA for use in immunotherapy against different types of cancers

Peptides displayed by HLA for use immunotherapy against different types of cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods

Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary class

Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers

Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods

Growing community of inventors

Tuebingen, Germany

Michael Roemer